Jana Pittman

Jana Pittman

Auto-generated profile, based on publicly available information

Jana Pittman

Royal Hospital for Women Sydney NSW

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2020 in Australian and New Zealand Journal of Obstetrics and Gynaecology
Verified
Journal Article
Closed access
PDF file
JPJana Pittman
Jana Pittman
LMLise Mogensen
Lise Mogensen
MBMats Brännström
Mats Brännström
WCWarren Chan
Warren Chan
NMNatalie Morrison
Natalie Morrison

8 April 2023 in Australian and New Zealand Journal of Obstetrics and Gynaecology
Verified
Journal Article
Open access
RDRebecca Deans
Rebecca Deans
JPJana Pittman
Jana Pittman
BGBrigitte Gerstl
Brigitte Gerstl
KHKoroush Haghighi
Koroush Haghighi
HPHenry Pleass
Henry Pleass
JAJason Anthony Abbott
Jason Anthony Abbott
Aims: The aim is to report the results of Australia's first uterus transplantation (UTx).Methods: Following long‐standing collaboration between the Swedish and Australian teams, Human Research Ethics approval was obtained to perform six UTx procedures in a collaborative multi‐site research study (Western Sydney Local District Health 2019/ETH13038), including Royal Hospital for Women, Prince of Wales Hospital, and Westmead Hospital in New Souh Wales. Surgeries were approved in both the live donor (LD) and deceased donor models in collaboration with the inaugural Swedish UTx team.Results: This is the first UTx procedure to occur in Australia, involving a mother donating her uterus to her daughter. The total operative time for the donor was 9 h 54 min. Concurrently, recipient surgery was synchronised to minimise graft ischaemic time, and the total operative time for the recipient was 6 h 12 min. Surgery was by laparotomy in the LD and recipient. The total warm ischaemic time of the graft was 1 h 53 min, and the cold ischaemic time was 2 h 17 min (total ischaemic time 4 h 10 min). The patient's first menstruation occurred 33 days after the UTx procedure.Conclusion: Twenty‐five years of Swedish and Australian collaboration has led to Australia's first successfully performed UTx surgery at The Royal Hospital for Women, Sydney, Australia.

28 March 2024 in Australian and New Zealand Journal of Obstetrics and Gynaecology
Verified
Journal Article
Open access
PDF file
JPJana Pittman
Jana Pittman
MBMats Brännström
Mats Brännström
NKNeill Keily
Neill Keily
BGBrigitte Gerstl
Brigitte Gerstl
ECElena Cavazzoni
Elena Cavazzoni
RDRebecca Deans
Rebecca Deans
Aim: Uterus transplantation (UTx) is an emerging treatment option for women with uterine factor infertility (UFI) or the absence of a functional uterus. This is the study protocol for the first human UTx clinical trial in Australia.Materials and Methods: This protocol outlines the approved training program used to plan, diagnose, screen, and treat patients who may be eligible for UTx using living and deceased donors. This multi‐site clinical research study includes three tertiary hospital sites within New South Wales (NSW), Australia – Prince of Wales, Royal Hospital for Women and Westmead Hospitals. Our UTx protocol is based on that used by our collaborative partner, the inaugural UTx team in Gothenburg, Sweden. The Swedish UTx team provides ongoing preceptorship for the Australian UTx team. Ethics approval for six UTx procedures using living or deceased donors (Western Sydney Local Health District Human Research Ethics Committee: 2019/ETH138038) was granted in 2020.Results: Results from surgeries and live births will be published. Data will be prospectively entered into the registry of the International Society of Uterus Transplantation (ISUTx), a sub‐section of The Transplantation Society (TTS). Trial Id: ACTRN12622000917730.Discussion: A multidisciplinary research team has been formed between three tertiary hospitals in Sydney – The Royal Hospital for Women, Prince of Wales and Westmead Hospitals; and with the Swedish UTx, University of Gothenburg. The Swedish team pioneered animal and human UTx studies since 1998, including publishing the first live birth after UTx. (1) This Australian trial commenced in January 2023.Conclusion: Uterus transplantation gives women with UFI the opportunity to be gestational and genetic mothers. It is a complex procedure for both the donor and recipient, with medical and surgical risks. An extensive multidisciplinary approach is required to optimise patient safety and graft outcomes. This protocol outlines our Australian UTx team strategy for screening, recruitment, surgical approach, and clinical management of UTx recipients and donors.

3 July 2023 in Australian and New Zealand Journal of Obstetrics and Gynaecology
Verified
Journal Article
Open access
JPJana Pittman
Jana Pittman
JAJason Anthony Abbott
Jason Anthony Abbott
ECElena Cavazzoni
Elena Cavazzoni
HPHenry Pleass
Henry Pleass
MBMats Brännstrom
Mats Brännstrom
RDRebecca Deans
Rebecca Deans
Background: Uterus transplantation is an emerging treatment option for uterine factor infertility. Most uterus transplantation research programs use living donors, although this comes with considerable surgical and psychological risks and not all women desiring uterus transplantation will have an available living donor. A deceased donor program eliminates donor risks; however, the availability of deceased uterus donors is currently unknown in Australia.Aims: To establish the feasibility of a deceased donor uterus transplantation program in Australia and consider expanded inclusion criteria for this model.Materials and Methods: A retrospective review of the New South Wales (NSW) Organ and Tissue Donation Service database was undertaken to identify potential deceased uterus donors, with comparison to the broad deceased donor inclusion criteria from three international uterus transplantation trials including female, brain‐dead, multi‐organ donation, no major abdominal surgery, and <60 years of age.Results: Between January 1, 2018, and December 31, 2022, 648 deceased donors were available in NSW. Of these, 43% (279/648) were female and 67% of the women (187/279) were also multi‐organ donors. When the brain‐dead donor‐only and age criteria (<60 years) were applied, a total of 107 deceased donors met the available criteria for uterus transplantation, with an average of 21 deceased donors per year in NSW.Conclusions: There appears to be adequate deceased donor organ availability to establish a deceased uterus transplantation program in NSW, Australia. Should interest in uterus transplantation increase, including criteria such as older and nulliparous donors could increase organ availability for a uterus transplantation program.

28 February 2025 in Frontiers in Transplantation
Verified
Journal Article
Open access
PDF file
JPJana Pittman
Jana Pittman
BGBrigitte Gerstl
Brigitte Gerstl
ECElena Cavazzoni
Elena Cavazzoni
NRNatasha Mireille Rogers
Natasha Mireille Rogers
MLMianna Lotz
Mianna Lotz
\P\R\Njana Pittman
\R\Njana Pittman
Background: Uterus transplant now offers an alternative deceased donation treatment option for women with uterine infertility. Limited research exists on religious opinions that may impact the addition of the uterus to current multi-organ deceased donor programsObjective: To explore the acceptability of uterus transplantation and deceased uterus donation across different religious groups.Design: A cross-sectional survey of 2,497 participants was conducted between October 2022 and January 2023 in NSW Australia. Australia is a culturally and religiously diverse nation with over 60% of people identifying with a religion, including Christianity (43%), Islam (3.2%), Buddhism (2.7%), Hinduism (2.4%). This survey captured awareness and attitudes towards deceased uterus donation. Descriptive statistics and regression analyses were used to explore factors influencing organ donation and next-of-kin perceptions.Results: A total of 2,497 respondents completed the survey. Christians had greater awareness of organ donation but were less likely to be registered donors, or consent to uterus donation. Those of Hindu faith were less likely to be registered organ donors. Next-of-kin from the Islamic faith were reluctant to consent to organ donation if the donor's pre-death wishes were unknown, and less likely to consent to uterus donation. Participants identifying as Buddhist had a higher awareness of uterus transplantation.Conclusion: Organ donor awareness and consent rates varied across religious groups, including for uterus donation. Differences may stem from varying beliefs about bodily integrity, and reproductive rights, which may influence attitudes toward uterus donation. Tailored culturally and linguistically sensitive educational campaigns should address the unique aspects of uterus donation.

23 May 2025 in Medical Journal of Australia
Verified
Journal Article
Open access
RDRebecca Deans
Rebecca Deans
BGBrigitte Gerstl
Brigitte Gerstl
ASAntonia W Shand
Antonia W Shand
SLSarah Lyons
Sarah Lyons
ABAaron Budden
Aaron Budden
JAJason Abbott
Jason Abbott
Objective: To report the first live birth following uterus transplantation in Australia.Study design: Case report.Setting, participant: The first participant in the uterus transplantation research study program at the Royal Hospital for Women, the Prince of Wales Hospital, and Westmead Hospital in Sydney.Main outcome measures: Clinical course after uterus transplantation; course of the subsequent pregnancy until delivery.Results: The immunosuppression regimen following uterus transplantation on 10 January 2023 was similar to that used for low immunologic risk kidney transplantation. It included induction therapy (basiliximab on days 0 and 4, methylprednisolone on days 0 and 1), followed by maintenance therapy with oral tacrolimus, prednisolone, and mycophenolate mofetil (MMF). The prednisolone dose was steadily tapered over twelve weeks to a low maintenance dose (from 25 mg to 5 mg daily); MMF was replaced with azathioprine during week 9, and tacrolimus was continued throughout the pregnancy. There was no evidence of rejection. A frozen grade 1 blastocyst was transferred during a natural ovulatory cycle 101 days (fifteen weeks) after transplantation; clinical pregnancy was successfully initiated. The woman developed gestational diabetes at 20 weeks and was treated with insulin. A healthy boy was born by planned caesarean delivery at 37 weeks; he weighed 2990 g, with Apgar scores of 7 at one minute and 9 at five minutes. Intrapartum haemorrhage (estimated 2500 mL) led to iron infusion after delivery. The woman and her infant were discharged from the hospital five days after the birth. The infant was breastfed, but the woman experienced recurrent episodes of mastitis that were managed with oral antibiotics, and intravenous antibiotics during two hospital admissions. Eight weeks after birth she commenced weaning the infant. Neither the woman nor her infant experienced serious complications.Conclusion: The first live birth following uterus transplantation in Australia indicates that the procedure could be adopted here as an assisted reproductive technology for women with uterine factor infertility.Trial registration: Australian and New Zealand Clinical Trials registry, ACTRN12622000917730.